Viread Tablet, Coated
NDC Package 61958-0404-1
Package Information
Viread (tenofovir disoproxil fumarate) tablets is tenofovir is used with other HIV medications to help control HIV infection. This formulation utilizes a tablet, coated delivery system. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-0404 and is authorized under FDA application NDA021356.
Identification & Billing
- RxCUI: 1243227 - tenofovir disoproxil fumarate 250 MG Oral Tablet
- RxCUI: 1243227 - tenofovir disoproxil fumarate 250 MG (equivalent to tenofovir disoproxil 204 MG) Oral Tablet
- RxCUI: 1243229 - Viread 250 MG Oral Tablet
- RxCUI: 1243229 - tenofovir disoproxil fumarate 250 MG Oral Tablet [Viread]
- RxCUI: 1243229 - Viread 250 MG (equivalent to tenofovir disoproxil 204 MG) Oral Tablet
Clinical Specifications
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor - [EPC] (Established Pharmacologic Class)
- Nucleoside Reverse Transcriptase Inhibitors - [MoA] (Mechanism of Action)
- Nucleosides - [CS]
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-0404 - Viread
- 61958-0404-1 - 30 TABLET, COATED in 1 BOTTLE, PLASTIC
- 61958-0404 - Viread
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-0404-1 identifies a specific commercial package of 30 tablet, coated in 1 bottle, plastic of Viread, a human prescription drug labeled by Gilead Sciences, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 30 billable units per package. This tablet, coated is formulated for oral use and contains tenofovir disoproxil fumarate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gilead Sciences, Inc. on January 18, 2012. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Tenofovir is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Tenofovir belongs to a class of drugs known as nucleotide reverse transcriptase inhibitors (NRTIs). Tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, do all of the following: (1) continue to take all HIV medications exactly as prescribed by your doctor, (2) always use an effective barrier method (latex or polyurethane condoms/dental dams) during all sexual activity, and (3) do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details. Tenofovir is also used to treat a certain type of liver infection called chronic hepatitis B infection. It helps to decrease the amount of hepatitis B virus in your body by interfering with virus growth.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958040401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.